(Reuters) - Several Indian pharmaceutical companies are working to develop or manufacture at least eight anti-COVID-19 formulations as the world's largest producer of vaccines prepares for a massive response to the coronavirus pandemic.
India, which has itself been badly hit by the pandemic with nearly 10 million infections, the second-highest in the world, is focusing on affordable vaccines instead of the expensive messenger RNA shots of Pfizer Inc and Moderna Inc.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!